Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology.

"Authors’ disclosures available online (http://j-alz.com/manuscript-disclosures/15-0020r1)."

"We thank all the participants who took part in this study and the clinicians who referred participants. The AIBL study (http://www.AIBL.csiro.au) is a collaboration between CSIRO, Edith Cowan University (ECU), The Florey Institute of Neuroscience and Mental Health (FINMH), National Ageing Research Institute (NARI) and Austin Health. It also involves support from CogState Ltd., Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The study received funding support from CSIRO, the Science and Industry Endowment Fund (www.SIEF.org.au), NHMRC and Dementia Collaborative Research Centres (DCRC), Alzheimer’s Australia (AA), Alzheimer’s Association, and the McCusker Alzheimer’s Research Foundation. This work was supported by the Alzheimer’s Society, the NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at the South London, Maudsley NHS Foundation Trust and Kings College London. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. SOMAscan and SOMAmer are trademarks of SomaLogic, Inc. Sally Nelson and Steven Williams are employees of SomaLogic, Inc, and the proteomic assay reported in this manuscript was performed by them using reagents supplied by SomaLogic, Inc. Steven Kiddle is supported by an MRC Career Development Award in Biostatistics (MR/L011859/1). A portion of this work was funded by GE Healthcare and Janssen R&D. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Department of Health, GEHC and Janssen."